Company Description
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.
The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia.
The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726.
The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024.
MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Hyung Heon Kim |
Contact Details
Address: 545 Concord Avenue, Suite 210 Cambridge, Massachusetts 02138 United States | |
| Phone | 857 702 9600 |
| Website | metaviatx.com |
Stock Details
| Ticker Symbol | MTVA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638287 |
| ISIN Number | US64132R5037 |
| Employer ID | 47-2389984 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hyung Heon Kim | Chief Executive Officer, President and Director |
| Marshall H. Woodworth | Chief Financial Officer |
| Dr. Mi-Kyung Kim | Chief Scientific Officer |
| Robert Homolka | Senior Vice President of Clinical Operations |
| Dr. W. Christopher Fang M.D. | Consulting Chief Medical Officer and Advisor |
| Michael C. Pine | Senior Vice President of Business Development Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 10, 2026 | 8-K | Current Report |
| Apr 7, 2026 | 424B3 | Prospectus |
| Apr 6, 2026 | EFFECT | Notice of Effectiveness |
| Apr 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 3, 2026 | POS AM | Post-Effective amendments for registration statement |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 26, 2026 | 10-K | Annual Report |